Alexza: Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insights | Alexza Pharma, Xenon Pharma, GW Pharma, Equilibre Biopharma, Takeda Pharma, Abide therapeutics, Otsuka pharma

The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. " Epilepsy Pipeline Insight, 2024 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Epilepsy Market. Some of the key takeaways from the Epilepsy Pipeline Report: Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years. Epilepsy companies working in the treatment market are Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc, and others, are developing therapies for the Epilepsy treatment Companies across the globe are diligently working toward developing novel Epilepsy treatment therapies with a considerable amount of success over the years. Epilepsy companies working in the treatment market are Elium Therapeutics, CombiGene, Ovid Therapeutics, Otsuka Pharmaceutical Co.,Ltd., SK Biopharmaceuticals, Receptor Life Sciences, Cerebral Therapeutics, Equilibre Biopharmaceuticals, Cerevel Therapeutics, Engrail Therapeutics, Amzell, Xenon Pharmaceuticals Inc, and others, are developing therapies for the Epilepsy treatment Emerging Epilepsy therapies in the different phases of clinical trials are- Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years. In January 2023, In order to assess the efficacy and safety of AMZ002 in the treatment of infantile spasms, a rare form of epilepsy, Amzell started a randomised, open-label superiority study. The primary goal of this study is to compare AMZ002 and Vigabatrin for treating infantile spasms (IS) in participants who have just received a diagnosis In March 2023, Preclinical data supporting IAMA Therapeutics' IAMA-6 programme in focal refractory epilepsy will be presented at the 75th American Academy of Neurology (AAN) Annual Meeting, which will be held from April 22-27 in Boston, Massachusetts. IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to improve the lives of people suffering from brain disorders In February 2023, The Phase 2 clinical study of ADX71149 (JNJ-40411813) for the treatment of epilepsy was completed, according to an announcement from Addex Therapeutics. Metabotropic glutamate type 2 (mGlu2) receptor-positive allosteric modulator (PAM) ADX71149 is selective. The experiment is being run by Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson's Janssen Pharmaceutical Companies In January 2023, EQU-001 , a novel anti-inflammatory anti-seizure drug, is administered as once-daily oral adjunctive therapy for focal seizures in adults with epilepsy. Equilibre Biopharmaceuticals Corp. reported positive topline results from the Phase 2 clinical trial evaluating the clinical safety, tolerability, and preliminary efficacy of EQU-001. The EQU-001 study's findings are positive since they show outstanding tolerability and encouraging efficacy for adult patients with focal epilepsy, particularly for those who have seizures that are challenging to manage. Emerging Epilepsy therapies in the different phases of clinical trials are- Kv7 Program, CG 01, OV329, OPC-214870, SKL24741, RLS103, CT-010, EQU 001, Darigabat, ENX-101, AMZ002, XEN496, and others are expected to have a significant impact on the Epilepsy market in the coming years. In January 2023, In order to assess the efficacy and safety of AMZ002 in the treatment of infantile spasms, a rare form of epilepsy, Amzell started a randomised, open-label superiority study. The primary goal of this study is to compare AMZ002 and Vigabatrin for treating infantile spasms (IS) in participants who have just received a diagnosis In March 2023, Preclinical data supporting IAMA Therapeutics' IAMA-6 programme in focal refractory epilepsy will be presented at the 75th American Academy of Neurology (AAN) Annual Meeting, which will be held from April 22-27 in Boston, Massachusetts. IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to improve the lives of people suffering from brain disorders In February 2023, The Phase 2 clinical study of ADX71149 (JNJ-40411813) for the treatment of epilepsy was completed, according to an announcement from Addex Therapeutics. Metabotropic glutamate type 2 (mGlu2) receptor-positive allosteric modulator (PAM) ADX71149 is selective. The experiment is being run by Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson's Janssen Pharmaceutical Companies In January 2023, EQU-001 , a novel anti-inflammatory anti-seizure drug, is administered as once-daily oral adjunctive therapy for focal seizures in adults with epilepsy. Equilibre Biopharmaceuticals Corp. reported positive topline results from the Phase 2 clinical trial evaluating the clinical safety, tolerability, and preliminary efficacy of EQU-001. The EQU-001 study's findings are positive since they show outstanding tolerability and encouraging efficacy for adult patients with focal epilepsy, particularly for those who have seizures that are challenging to manage. Epilepsy Overview A chronic neurological condition called epilepsy is characterised by frequent, recurrent convulsions that cause strange behaviour. Due to the many seizure forms, underlying conditions, and varying degrees of severity, it might be seen as a spectrum disorder. Get a Free Sample PDF Report to know more about Epilepsy Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/epilepsy-pipeline-insight Emerging Epilepsy Drugs Under Different Phases of Clinical Development Include: Kv7 Program: Elium Therapeutics CG 01: CombiGene OV329: Ovid Therapeutics OPC-214870: Otsuka Pharmaceutical Co.,Ltd. SKL24741: SK Biopharmaceuticals RLS103: Receptor Life Sciences CT-010: Cerebral Therapeutics EQU 001: Equilibre Biopharmaceuticals Darigabat: Cerevel Therapeutics ENX-101: Engrail Therapeutics AMZ002: Amzell XEN496: Xenon Pharmaceuticals Inc Kv7 Program: Elium Therapeutics CG 01: CombiGene OV329: Ovid Therapeutics OPC-214870: Otsuka Pharmaceutical Co.,Ltd. SKL24741: SK Biopharmaceuticals RLS103: Receptor Life Sciences CT-010: Cerebral Therapeutics EQU 001: Equilibre Biopharmaceuticals Darigabat: Cerevel Therapeutics ENX-101: Engrail Therapeutics AMZ002: Amzell XEN496: Xenon Pharmaceuticals Inc Epilepsy Route of Administration Epilepsy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as Oral Parenteral Intravenous Subcutaneous Topical Oral Parenteral Intravenous Subcutaneous Topical Epilepsy Molecule Type Epilepsy Products have been categorized under various Molecule types, such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Epilepsy Pipeline Therapeutics Assessment Epilepsy Assessment by Product Type Epilepsy By Stage and Product Type Epilepsy Assessment by Route of Administration Epilepsy By Stage and Route of Administration Epilepsy Assessment by Molecule Type Epilepsy by Stage and Molecule Type Epilepsy Assessment by Product Type Epilepsy By Stage and Product Type Epilepsy Assessment by Route of Administration Epilepsy By Stage and Route of Administration Epilepsy Assessment by Molecule Type Epilepsy by Stage and Molecule Type DelveInsight's Epilepsy Report covers around 90+ products under different phases of clinical development like Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Late-stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Further Epilepsy product details are provided in the report. Download the Epilepsy pipeline report to learn more about the emerging Epilepsy therapies Some of the key companies in the Epilepsy Therapeutics Market include: Key companies developing therapies for Epilepsy are - Alexza Pharmaceuticals, Xenon Pharmaceuticals, GW Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, H. Lundbeck A/S, Spark Therapeutics, Equilibre Biopharmaceuticals, ES Therapeutics, Supernus Pharmaceuticals, Inc., MGC Pharmaceuticals, Engrail Therapeutics INC, SK biopharmaceuticals, Longboard Pharmaceuticals, Janssen Research & Development, LLC, Equilibre Biopharmaceuticals, Cerevel Therapeutics, LLC, Neurona Therapeutics, Praxis Precision Medicines, UCB Pharma, Receptor Life Sciences, NeuroPro Therapeutics, Inc., Avicanna, Amring Pharmaceuticals Inc., Ovid Therapeutics, Addex Therapeutics, IAMA Therapeutics, CODA Biotherapeutics, Cerebral Therapeutics, Engrail Therapeutics, and others. Epilepsy Pipeline Analysis: The Epilepsy pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of E